title: The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB.
abstract: Since the first report documenting that HIV-1 Vpr was involved in the stimulation of transactivation of several unrelated promoters, little additional information has been reported. By using transient transfection experiments, we confirmed and extended these previously reported data. Further in vivo experiments showed that Vpr can co-operatively stimulate transactivation activity of a minimal promoter containing one GAL4 DNA-binding site, when it is co-expressed with different heterologous activator domains fused to GAL4 DNA-binding domain. Thus, Vpr could transactivate in concert with an activator domain, but has no effect on the transactivation of a minimal promoter in the absence of activator protein. To investigate whether Vpr can interact with components of the basal transcriptional machinery, in vitro protein-protein binding assays were performed using either translated, radiolabeled Vpr or TFIIB proteins and glutathione S-transferase Vpr or TFIIB chimeric proteins. We demonstrated that the portion of Vpr ranging from amino acids 15 to 77 interacts specifically with the basal transcription factor TFIIB. Also, our data indicated that the N-terminal domain of TFIIB is required for the interaction.
authors.affiliation: INSERM U372, Pathogénie des infections à lentivirus BP 178, Marseille, France.
authors.forename: I
authors.initials: I
authors.lastname: Agostini
authors.forename: J M
authors.initials: JM
authors.lastname: Navarro
authors.forename: F
authors.initials: F
authors.lastname: Rey
authors.forename: M
authors.initials: M
authors.lastname: Bouhamdan
authors.forename: B
authors.initials: B
authors.lastname: Spire
authors.forename: R
authors.initials: R
authors.lastname: Vigne
authors.forename: J
authors.initials: J
authors.lastname: Sire
mesh_terms: D017500:Adenovirus E1A Proteins / Q000235:genetics / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D017124:Conserved Sequence; D004268:DNA-Binding Proteins; D005656:Fungal Proteins / Q000235:genetics / Q000378:metabolism; D015967:Gene Expression Regulation, Viral; D016336:Gene Products, vpr / Q000235:genetics* / Q000378:metabolism*; D017930:Genes, Reporter; D005982:Glutathione Transferase / Q000235:genetics / Q000378:metabolism; D016325:HIV Long Terminal Repeat; D017405:Herpes Simplex Virus Protein Vmw65 / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D016328:NF-kappa B / Q000096:biosynthesis; D010957:Plasmids / Q000235:genetics; D011401:Promoter Regions, Genetic; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D029701:Saccharomyces cerevisiae Proteins; D016329:Sp1 Transcription Factor / Q000235:genetics / Q000378:metabolism; D016385:TATA Box; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015534:Trans-Activators / Q000235:genetics* / Q000378:metabolism; D035581:Transcription Factor TFIIB; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D017500:Adenovirus E1A Proteins; D004268:DNA-Binding Proteins; D005656:Fungal Proteins; C052130:GAL4 protein, S cerevisiae; D016336:Gene Products, vpr; D017405:Herpes Simplex Virus Protein Vmw65; D016328:NF-kappa B; D011993:Recombinant Fusion Proteins; D029701:Saccharomyces cerevisiae Proteins; D016329:Sp1 Transcription Factor; D015534:Trans-Activators; D035581:Transcription Factor TFIIB; D014157:Transcription Factors; D005982:Glutathione Transferase; D013755:Tetradecanoylphorbol Acetate